Company profile: ImaginAb
1.1 - Company Overview
Company description
- Provider of molecular imaging solutions for cancer and autoimmune disease management by re-engineering antibodies into small proteins. Offers non-invasive CD8 ImmunoPET to visualize CD8-positive T cells across the body and assess treatment effectiveness, develops therapeutic radiopharmaceuticals using antibody fragment platforms, and supports clinical trials through CD8 ImmunoPET implementation and partnerships.
Products and services
- CD8 ImmunoPET Imaging: A non-invasive molecular imaging system that maps immune response by visualizing CD8-positive T cells across the entire body to assess treatment effectiveness using re-engineered antibody small proteins
- Clinical Trials Support: Trial-focused guidance that delivers implementation of CD8 ImmunoPET technology in clinical studies, including partnership coordination with pharmaceutical and biotech companies to architect study integration
- Therapeutic Radiopharmaceuticals: Antibody-fragment-based therapeutic development that engineers radiopharmaceuticals using platform technologies to produce targeted treatment options for cancer and autoimmune diseases
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to ImaginAb
Century Therapeutics
HQ: United States
Website
- Description: Provider of iPSC-derived allogeneic NK and T cell therapies for cancer and autoimmune diseases, including CNTY-101 targeting CD19-positive B-cell lymphomas (Phase 1 ELiPSE-1). Offers CRISPR-MAD7 mediated HDR gene editing, Allo-Evasion technology for immune evasion and repeat dosing, CAR and protein engineering, and common engineered iPSC progenitors to accelerate development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Century Therapeutics company profile →
SmartHealth Dx
HQ: United States
Website
- Description: Provider of precision diagnostics addressing unmet clinical needs in vascular, metabolic, and oncological diseases, including SmartVascular Dx (blood test for vascular inflammation and stroke risk), SmartLung Dx (noninvasive test to identify benign lung nodules), SmartKidney Dx (metastasis risk in kidney disease), SmartScience Dx (~195,000-sample serum repository for biomarker discovery), and SmartPath Dx (real-time pathology imaging).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SmartHealth Dx company profile →
U-Systems
HQ: United States
Website
- Description: Provider of automated breast ultrasound systems and software that deliver automated breast scans to assist radiologists in detecting breast cancer, particularly in women with dense breast tissue.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full U-Systems company profile →
MediWise
HQ: United Kingdom
Website
- Description: Provider of medical research and development, pioneering cutting-edge wireless devices for medical diagnostics and monitoring.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MediWise company profile →
ME Therapeutics
HQ: Canada
Website
- Description: Provider of biotechnology drug discovery and development focused on myeloid cell-targeted immuno-oncology therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ME Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for ImaginAb
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to ImaginAb
2.2 - Growth funds investing in similar companies to ImaginAb
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for ImaginAb
4.2 - Public trading comparable groups for ImaginAb
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →